Novo Nordisk A/S (NONOF)
ValueMarkers Composite Index
63% above intrinsic value ($16)
Novo Nordisk A/S (NONOF) — VMCI valuation read
NONOF screens at VMCI 64/100, a 14-point gap above the Healthcare sector median (50). For a mid-cap Novo Nordisk A/S share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
NONOF has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: NONOF trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.5x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Novo Nordisk A/S.
NONOF fell 3.9% over the trailing 7 days, with a -19.8% read on a 30-day basis.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.